Navigation Links
Scientists identify a novel mechanism for evolution of highly aggressive cancers
Date:6/27/2011

model to explain a subset of particularly aggressive cancers for which modern medicine does not have therapeutic options".

Another author of the work, Dr Ho Khek Yu, an endoscopic surgeon specializing in Barrett's esophagus and Head of the Department of Medicine at National University of Singapore, added "Recent efforts to prevent the formation of esophageal cancer by removing the cells forming Barrett's esophagus before they turn cancerous have met with considerable setbacks. The study suggests a new way to prevent esophageal cancers: target these embryonic cells before they can form Barrett's esophagus. If the method is successful, we will have eradicated one major risk factor of esophageal cancer."

Corresponding author Dr Frank McKeon of the GIS and Harvard Medical School said, "we now have a great deal of information about these unusual embryonic cells that give rise to Barrett's esophagus and are working with clinicians to develop novel monoclonal antibodies to eliminate these cells before they become malignant. This type of preventive therapy directed at the precursors of these cancers is the rational approach to stamping out the disease, which has risen five-fold in the last 30 years."

Dr Yusuke Yamamoto, a senior postdoctoral fellow at the GIS, expert in bioinformatics and stem cell biology, and co-first author of the publication, noted, "I am continually amazed by the speed with which mouse genetic models, bioinformatics, and stem cell biology come together in Singapore to provide such a vivid image of disease processes and identify genes that represent the most important prevention and therapeutic targets".

Profs Barbara Knowles and Davor Solter, Senior Principal Investigators of the Mammalian Development Laboratory at the Institute of Medical Biology in Singapore commented, "An excellent piece of scientific sleuthing with a tantalizing approach to cancer prevention".

Prof Lee Eng Hin, Executive Director of
'/>"/>

Contact: Winnie Serah Lim
limcp2@gis.a-star.edu.sg
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Singapore scientists discover how to control fate of stem cells
2. Scientists Zero In on Key Melanoma Links
3. Scientists develop first ever drug to treat Celtic gene in cystic fibrosis sufferers
4. Scientists Turn Memory On, Off in Rats With Flip of Switch
5. Scientists Pinpoint Parts of Brain That Help People Recognize Themselves
6. Several methods for early diagnosis of Alzheimers disease developed by European scientists
7. Scientists image beginning stages of ovarian cancer growth with time-lapse technique
8. Scientists identify key component in lethal lung cancer complication
9. Swine flu spread was much wider than first thought, scientists say
10. Einstein scientists find crucial molecule involved in spread of breast cancer
11. Scientists create humanized mouse model for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... AZ (PRWEB) , ... September 05, 2015 , ... ... Artists from China for an exclusive, one-night exhibition of their work at Paradise Valley ... exhibit on Friday, September 18, from 6-9 pm. The artists will be on hand ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... Insight Product Development has effectively doubled the size of its annual health tech ... medical device and digital health startups to compete for cash and prizes to ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Providence Fertility Center will host ... their fertility and egg freezing. , Date and Time: October 8, 2015 at Waterman ... This hip and informative event will discuss the basics of female fertility and egg ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... Association (CHPA) joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and ... rules constantly evolving in the consumer goods industry, it can be difficult for ...
(Date:9/4/2015)... ... September 04, 2015 , ... San ... available at CitiDent. CEREC is a newer method for creating restorations through innovative ... patients by eliminating the need for multiple appointments, CEREC produces restorations with total ...
Breaking Medicine News(10 mins):Health News:Paradise Valley Community College Announces Master Ceramic Artists & Exhibit 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2
... 2008) − University of Kentucky researchers have discovered a possible ... pressure. , Dr. Lisa Cassis and Dr. Alan Daugherty found ... but also significantly reduced artery-clogging lesions that are the leading ... death worldwide. , "In my many years of atherosclerosis ...
... Feb. 14 Following the,company,s announcement of ... its sports and nutritional product manufacturer subsidiary ... Inc., (OTC Bulletin Board: NNTN) http://www.naturalnutritioninc.com ... split of its common stock.,Each shareholder will ...
... Corp. (NASDAQ: NCST ; TSX: NCS) today announced ... narrowed to $4.0 million, or 22,cents per share, on ... loss,of $10.5 million, or 58 cents per share, on ... net loss for 2007 is primarily attributable to,the combined ...
... TeamStaff, Inc.,(Nasdaq: TSTF ), a national provider ... results for the first,quarter ended December 31, 2007., ... 31, 2007 was,$0.1 million as compared to a loss ... from continuing operations was $0.04 million or,$0.00 per share ...
... Protection ... Against Aetna,s Propofol Decision, NEW YORK, Feb. ... of Propofol, the "gold standard" anesthesia agent available,to patients ... amongst physicians, their associations and consumers.,Today, the Gastroenterologists and ...
... computer-aided detection (CAD) is more efficient than double reading ... in a double reading program, according to a study ... In addition, the readings with CAD had a significantly ... reading method consisted of the mammogram being first read ...
Cached Medicine News:Health News:Natural Nutrition Announces Effectiveness of Forward Split of Common Stock Following 2007 Record Revenue Year 2Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 2Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 3Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 4Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 5Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 6Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 7Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 8Health News:TeamStaff Reports First Quarter Net Income and $0.7 Million Income Improvement From Continuing Operations Over Prior Year 9Health News:National Health Care Alliance Welcomes New Members 2Health News:National Health Care Alliance Welcomes New Members 3Health News:National Health Care Alliance Welcomes New Members 4Health News:Single reader with CAD more efficient, yields fewer false positives, and possibly more sensitive 2
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
... The PowerLab/8SP is a high-performance data acquisition ... life science research applications that require up ... capable of recording at speeds of up ... to disk, and is compatible with instruments, ...
Three Figure Worth Type Test, this test is used for determining diplopia, suppression or fusion in children. Sturdy chrome flashlight comes with red/green glasses. Requires 3 D batteries which are no...
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
20 foot distance 22-1/2" X 11-1/2". This test for illiterate patients has HOTV letters on one side and Allen figures on the other....
Medicine Products: